Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

DJO Incorporated announces acquisition of Elastic Therapy

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the acquisition of Elastic Therapy, Inc. The acquisition closed yesterday, January 4, 2011.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

New research focusing on VTE presented at ASH Annual Meeting

The latest advances in the treatment of bleeding and clotting disorders will be presented today at the 52nd Annual Meeting of the American Society of Hematology, focusing on venous thrombeombolism, a potentially life-threatening disorder in which abnormal blood clots form in the veins and restrict the flow of blood. New studies examine risk-prediction models and cutting-edge treatment options for patients with VTE.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Patients undergoing plastic or reconstructive surgery should receive a risk assessment before their procedure to predict whether they'll develop potentially fatal blood clots in the legs or lungs, according to research at the University of Michigan Medical School. Researchers also found that 1 in 9 patients at highest risk based on that assessment will develop clots if not given clot-preventing medications after surgery.

19 Nov 2010

MEDRAD to offer RSNA attendees hands-on demonstration on P3T PA software

MEDRAD will offer RSNA attendees hands-on demonstrations of personalized-protocol software that individualizes CT Pulmonary Angiography (CTPA) contrast dosing, and has proven to increase the percentage of diagnostic-quality studies to rule out Pulmonary Embolism (PE) when compared to the institution's standard protocol potentially obviating the need to rescan the patient.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Warfarin taken along with herbal, dietary supplements may be dangerous

Herbal and dietary supplements are popular. People claim they make their joints feel better, their bones stronger, and their hearts healthier. But a recent study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City shows that many of these people may not realize their favorite supplement, mixed with prescription medications, may be putting their lives in danger, especially if they are taking warfarin - a blood-thinning medication commonly prescribed to patients living with atrial fibrillation to lower their risk of stroke.

17 Nov 2010

Researchers hope to prevent VTE complication in cancer patients

A major study is under way at The University of Nottingham which could lead to better prevention of a serious and sometimes fatal complication in cancer patients.

12 Nov 2010

Covidien granted FDA 510(k) clearance for Kendall SCD Sleeve and Kendall SCD 700 Series Controller

Covidien, a leading global provider of healthcare products and recognized innovator in intermittent pneumatic compression (IPC), today announced 510(k) clearance from the U.S. Food and Drug Administration for the Kendall SCD™ Sequential Compression Comfort Sleeve and Kendall SCD™ 700 Series Controller. The new system will be launched next month in the U.S. and will deliver an improved level of comfort for patients, while reducing the risk of venous thromboembolism (VTE).

4 Nov 2010

Venous Disease Coalition launches new VTE Toolkit for health professionals

The Vascular Disease Foundation's Venous Disease Coalition announced the launch of its new VTE Toolkit, A Practical Overview for Health Professionals. This toolkit was developed by the Venous Disease Coalition (VDC).

28 Oct 2010

New national campaign to drive awareness on DVT and PE prevention in women

As many as 600,000 people are affected by deep vein thrombosis (DVT) and pulmonary embolism (PE) every year, and more than half of those are never diagnosed. Some people experience swelling and varying levels of discomfort in the affected area, and some don't feel anything at all. But the symptoms of DVT can be similar to other conditions, like a pulled muscle, and because some people with DVT do not have any symptoms, there is often a delay in diagnosis. That's when DVT can be fatal.

28 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Gene therapy may reverse pulmonary hypertension

A Heart and Stroke Foundation researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.

25 Oct 2010

ACS NSQIP recognizes Christiana Care Health System as participating hospital

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Christiana Care Health System as one of 26 ACS NSQIP participating hospitals in the United States that have achieved exemplary outcomes for surgical patient care.

20 Oct 2010

Hospital mortality rates decline by 7.98% from 2007 to 2009

A new independent study by HealthGrades of patient outcomes at America's hospitals found that patients at 5-star rated hospitals had a 72% lower risk of dying when compared with patients at 1-star-rated hospitals -- an enormous gap that has held steady over the past years even as overall mortality rates have improved.

20 Oct 2010